India's Pharmaceutical Landscape: Quality Control Challenges Unveiled

The Indian drug regulator has ordered the recall of around 45 medicines due to quality issues and is pursuing legal actions against five manufacturers of spurious drugs. Contrary to reports, these medicines were not fake but did not meet standard quality norms. Regular testing identifies such issues for corrective actions.

India's drug regulatory authority has mandated the recall of approximately 45 medications due to failure in meeting quality standards, while initiating actions against five producers of spurious drugs.

Responding to queries at the CII Pharma and Life Sciences summit, Drugs Controller General Rajeev Singh Raghuvanshi clarified that contrary to recent reports, the medicines were not banned as fake but were categorized as not up to standard quality. Only five were identified as spurious.

The CDSCO conducts routine sampling of over 2,000 drugs monthly, detecting 40-50 that fail quality parameters. While addressing regulatory measures, Raghuvanshi underlined ongoing efforts to trace and prosecute offenders within the supply chain.

(With inputs from agencies.)